These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 18611988)

  • 1. Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid.
    Hestvik AL; Skorstad G; Price DA; Vartdal F; Holmoy T
    Mult Scler; 2008 Jul; 14(6):749-58. PubMed ID: 18611988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glatiramer acetate-specific human CD8(+) T cells: increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment.
    Dressel A; Vogelgesang A; Brinkmeier H; Mäder M; Weber F
    J Neuroimmunol; 2006 Dec; 181(1-2):133-40. PubMed ID: 17084909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of glatiramer acetate to modify the peripheral T cell repertoire of relapsing-remitting multiple sclerosis patients.
    Berthelot L; Miqueu P; Pettré S; Guillet M; Moynard J; Wiertlewski S; Lefrère F; Brouard S; Soulillou JP; Laplaud DA
    Clin Immunol; 2010 Apr; 135(1):33-42. PubMed ID: 20116333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy.
    Ziemssen T; Kümpfel T; Schneider H; Klinkert WE; Neuhaus O; Hohlfeld R
    J Neurol Sci; 2005 Jun; 233(1-2):109-12. PubMed ID: 15869765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role.
    Liblau R
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S17-23. PubMed ID: 20106343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory potential and migratory capacities across human brain endothelial cells of distinct glatiramer acetate-reactive T cells generated in treated multiple sclerosis patients.
    Kim HJ; Biernacki K; Prat A; Antel JP; Bar-Or A
    Clin Immunol; 2004 Apr; 111(1):38-46. PubMed ID: 15093550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis.
    Salama HH; Hong J; Zang YC; El-Mongui A; Zhang J
    Brain; 2003 Dec; 126(Pt 12):2638-47. PubMed ID: 12937077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis?
    Jee Y; Liu R; Bai XF; Campagnolo DI; Shi FD; Vollmer TL
    Int Immunol; 2006 Apr; 18(4):537-44. PubMed ID: 16481342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and functional activity of chemokine receptors in glatiramer acetate-specific T cells isolated from multiple sclerosis patient receiving the drug glatiramer acetate.
    Høglund RA; Hestvik AL; Holmøy T; Maghazachi AA
    Hum Immunol; 2011 Feb; 72(2):124-34. PubMed ID: 20977917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis patients.
    Ruggieri M; Pica C; Lia A; Zimatore GB; Modesto M; Di Liddo E; Specchio LM; Livrea P; Trojano M; Avolio C
    J Neuroimmunol; 2008 Jul; 197(2):140-6. PubMed ID: 18555539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate.
    Duda PW; Krieger JI; Schmied MC; Balentine C; Hafler DA
    J Immunol; 2000 Dec; 165(12):7300-7. PubMed ID: 11120865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis.
    Valenzuela RM; Costello K; Chen M; Said A; Johnson KP; Dhib-Jalbut S
    Mult Scler; 2007 Jul; 13(6):754-62. PubMed ID: 17613604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bystander modulation of chemokine receptor expression on peripheral blood T lymphocytes mediated by glatiramer therapy.
    Allie R; Hu L; Mullen KM; Dhib-Jalbut S; Calabresi PA
    Arch Neurol; 2005 Jun; 62(6):889-94. PubMed ID: 15956159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor.
    Ziemssen T; Kümpfel T; Klinkert WE; Neuhaus O; Hohlfeld R
    Brain; 2002 Nov; 125(Pt 11):2381-91. PubMed ID: 12390966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glatiramer acetate: mechanisms of action in multiple sclerosis.
    Schrempf W; Ziemssen T
    Autoimmun Rev; 2007 Aug; 6(7):469-75. PubMed ID: 17643935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4.
    Basile E; Gibbs E; Aziz T; Oger J
    J Neuroimmunol; 2006 Aug; 177(1-2):161-6. PubMed ID: 16765453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy.
    Karussis D; Teitelbaum D; Sicsic C; Brenner T;
    J Neuroimmunol; 2010 Mar; 220(1-2):125-30. PubMed ID: 20153903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic and functional analysis of T cells cloned directly from the blood and cerebrospinal fluid of patients with multiple sclerosis.
    Hafler DA; Buchsbaum M; Johnson D; Weiner HL
    Ann Neurol; 1985 Oct; 18(4):451-8. PubMed ID: 2416267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?
    Bar-Or A; Oger J; Gibbs E; Niino M; Aziz T; Renoux C; Alatab S; Shi FD; Campagnolo D; Jalili F; Rhodes S; Yamashita T; Fan B; Freedman MS; Panitch H; Arnold DL; Vollmer T
    Mult Scler; 2009 Aug; 15(8):959-64. PubMed ID: 19667022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythema nodosum and glatiramer acetate treatment in relapsing-remitting multiple sclerosis.
    Thouvenot E; Hillaire-Buys D; Bos-Thompson MA; Rigau V; Durand L; Guillot B; Camu W
    Mult Scler; 2007 Aug; 13(7):941-4. PubMed ID: 17881403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.